No Dose Adjustment Required for Invanz at GFR 62 mL/min
For a patient with a GFR of 62 mL/min receiving Invanz (ertapenem) 1 gram daily for 7 days, no renal dose adjustment is necessary. Continue the standard dose of 1 gram once daily via IV or IM administration 1.
Rationale
The FDA-approved prescribing information for Invanz clearly states that no dosage adjustment is required when creatinine clearance is >30 mL/min/1.73 m² 1. Your patient's GFR of 62 mL/min falls well above this threshold, placing them in the category of mild renal impairment where standard dosing remains appropriate.
Specific Dosing Parameters
- Standard dose: 1 gram once daily
- Route: IV infusion over 30 minutes or IM injection
- Duration: Up to 14 days for IV, up to 7 days for IM
- Your patient's 7-day course: Appropriate duration within approved limits
When Dose Adjustment IS Required
Dose reduction becomes necessary only when creatinine clearance drops to ≤30 mL/min/1.73 m²:
- CrCl ≤30 mL/min: Reduce to 500 mg once daily 1
- End-stage renal disease (CrCl ≤10 mL/min): 500 mg once daily 1
- Hemodialysis patients: 500 mg daily, with supplementary 150 mg dose if administered within 6 hours before dialysis 1
Important Clinical Caveat
Note the distinction between Invanz (ertapenem) and imipenem-cilastatin mentioned in your question. These are different carbapenems with distinct renal dosing requirements. The evidence provided includes multiple references to imipenem-cilastatin pharmacokinetics [2-3], but your question specifically asks about Invanz, which is the brand name for ertapenem. Ertapenem has more favorable once-daily dosing and requires adjustment only at lower GFR thresholds compared to imipenem.
Monitoring Recommendation
While no dose adjustment is needed, monitor renal function if the patient's clinical condition changes significantly during the 7-day treatment course, as critical illness can alter drug clearance unpredictably.